Since the inception of radionuclide therapies by John Lawrence and Saul Hertz over 80 y ago, little has changed regarding ...
Radiopharmaceutical therapy (RPT) delivers protracted, low absorbed dose rate radiation over time, with cellular DNA repair ...
Journal of Nuclear Medicine August 2026, jnumed.126.272179; DOI: https://doi.org/10.2967/jnumed.126.272179 ...
In the past decade, an increasing number of approved therapies with various mechanisms of action have become available for metastatic castration-resistant prostate cancer (mCRPC), but the associated ...
You do not have access to the full text of this article, the first page of the PDF of this article appears above. This article requires a subscription to view the full text. If you have a subscription ...
The Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 years by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of ...
68Ga-labeled nanobody (68Ga-NC-BCH) is a single-domain antibody–based PET imaging agent. We conducted a first-in-humans study of 68Ga-NC-BCH for PET to determine its in vivo biodistribution, ...
Journal of Nuclear Medicine August 2026, jnumed.126.272655; DOI: https://doi.org/10.2967/jnumed.126.272655 ...
Brain PET is a powerful imaging modality that directly reflects cerebral metabolic activity, making it an essential tool for human brain research. However, conventional brain PET typically requires ...
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the theranostic potential of a ...
Journal of Nuclear Medicine June 2026, jnumed.125.271392; DOI: https://doi.org/10.2967/jnumed.125.271392 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results